Nevro Corp is primarily active in the medical device industry.

The main competitors of Nevro Corp in the market include Medtronic, Abbott Laboratories, Boston Scientific Corporation, and Stryker Corporation.

Nevro Corp is a medical device company that specializes in developing innovative solutions for the treatment of chronic pain. Founded in 2006, Nevro has been a pioneer in the field of spinal cord stimulation. The company's flagship product, the Senza System, is designed to provide long-lasting pain relief without the side effects of traditional opioids. With a strong focus on research and development, Nevro has continued to expand its product portfolio and establish itself as a leader in the industry. Today, Nevro is trusted by healthcare professionals worldwide for its advanced therapies and commitment to improving patients' quality of life.

Nevro Corp, a leading medical device company, has achieved several significant milestones. Firstly, the company developed the breakthrough Senza® system, a spinal cord stimulation platform that offers superior pain relief for patients suffering from chronic pain. This innovative technology has revolutionized the field of neuromodulation. Furthermore, Nevro Corp successfully obtained FDA approval for the Senza system, allowing them to market it in the United States. The company has expanded its global presence as well, receiving regulatory approvals in various countries worldwide. These achievements have solidified Nevro Corp's position as a pioneering entity in the medical device industry, dedicated to improving the lives of patients worldwide.

Nevro Corp is primarily present in various countries and regions worldwide. The company has a global presence and operates in key markets including the United States, Europe, Australia, and Canada. With its innovative medical technology solutions, Nevro Corp aims to improve the lives of patients suffering from chronic pain across these regions.

Nevro Corp represents a strong commitment to improving the lives of patients suffering from chronic pain. With a focus on innovation and advanced technology, Nevro prioritizes patient-centered solutions. The company's corporate philosophy revolves around providing effective and long-lasting relief to individuals in need. Nevro Corp aims to enhance the quality of life by offering non-opioid, evidence-based therapies that deliver superior results. By combining scientific expertise, cutting-edge research, and a patient-centric approach, Nevro Corp strives to make a meaningful impact in the field of chronic pain management.

Analysts currently set an average price target of 8,87 USD for the Nevro LLC stock (median: 5,97 USD), implying +51,9 % versus the latest price. The consensus is based on 19 analyst ratings.

Nevro LLC Analyytikkojen kursstavoitteet 2026

19 analysts currently rate the Nevro LLC stock: 0 recommend buying, 15 holding and 4 selling. For 2026, analysts expect Nevro LLC to generate revenue of 424,42 M USD and earnings per share of −1,76 USD.

Nevro LLC Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Nevro LLC share trades at 5,04 EUR (5,84 USD).

The Nevro LLC share (NVRO) is listed on 4 stock exchanges, including: NYSE (NVRO), Frankfurt (1N7.F), Düsseldorf (1N7.DU), SIX (Zürich) (1N7.SW).

Nevro Corp is a globally operating, publicly traded company that specializes in the development and marketing of innovative medical products for the treatment of chronic pain. The company's business model is based on the use of groundbreaking technologies to alleviate pain in millions of patients worldwide. The company operates in two business segments: manufacturing and product services, as well as research and development. Product services include the marketing of both implanted and external pain relief devices, including the flagship product Senza®. These devices utilize a novel technology called HF10® to effectively combat pain. Unlike traditional devices that promise pain relief through electrical signals, HF10® uses state-of-the-art high-frequency technology to stimulate the spinal cord, resulting in deeper and more effective pain relief. In addition to the Senza® product line, Nevro also has several micro-catheter solutions in its portfolio. These catheters also use HF10® technology, but in a different way for pain treatment. The company is committed to continuously developing and bringing to market new, innovative pain relief solutions to improve the lives of patients worldwide. Nevro Corp's R&D department focuses on pain research and the development of pain relief technologies. The company collaborates with leading research institutions worldwide and invests sustainably in clinical research to improve the effectiveness of its products and obtain approvals and further market clearances in various countries. Furthermore, Nevro also offers a wide range of services to support hospitals and medical professionals in the provision of pain therapies and treatments. This includes a training program for medical personnel to ensure safe and effective use of the devices, as well as a support team available around the clock to address questions and technical issues. Nevro Corp is committed to creating a comprehensive pain relief experience for patients, healthcare professionals, and stakeholders. The company relies on a combination of innovative technologies, clinical research, and expert services to achieve this goal. In summary, Nevro Corp offers pain solutions based on its groundbreaking HF10® technology. The devices demonstrate high effectiveness in pain relief and are one of the most recommended pain therapies in modern clinics. The company continuously invests in research and development to improve its technology and introduce new products to the market. Nevro Corp supports doctors, medical personnel, and patients with a wide range of services to ensure that all parties have access to safe and effective pain treatment.

odotettu liikevaihto Nevro LLC on 424,42 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Nevro LLC on −66,29 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Nevro LLC:n hinta-voitto-suhde (P/E) on tällä hetkellä −3,31. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Nevro LLC-osakkeen arvostusta.

Nevro LLC:n hinta-myynti-suhde (P/S) on tällä hetkellä 0,52. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Nevro LLC-osakkeen arvostuskennuslukuna.

Nevro LLC:n Eulpool-laatuscore on 2/10.

Nevro LLC:n ISIN on US64157F1030. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Nevro LLC:n WKN on A12EPL. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Nevro LLC:n ticker on NVRO. Tämä pörssinoteeraus käytetään Nevro LLC-osakkeiden kauppaan pörssissä.

Nevro LLC maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Nevro LLC kuuluu sektoriin 'Terveydenhuolto'.

Nevro LLC:n osingot jaetaan valuutassa USD.